Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with 131I-metaiodobenzylguanidine with implications for the activity to administer

Medical Physics

Volumn 42, Issue 7, 2015, Pages 3969-3978

  Mínguez, Pablo ^a,b   Flux, Glenn ^c   Genollá, José ^b   Guayambuco, Sonía ^b   Delgado, Alejandro ^b   Fombellida, José Cruz ^b   Sjögreen Gleisner, Katarina ^a  

^a LUND UNIVERSITY   (Sweden)

^b HOSPITAL DE CRUCES   (Spain)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

131I mIBG; neuroblastoma; neuroendocrine tumors; treatment schedule

Indexed keywords

PATIENT TREATMENT; STATISTICS; TUMORS;

131I-MIBG; ABSORBED DOSE; NEUROBLASTOMAS; NEUROENDOCRINE TUMORS; PER UNIT; STANDARD DEVIATION; TREATMENT SCHEDULE; TUMOR PATIENT; TUMOR TREATMENT; WHOLE-BODY;

DOSIMETRY;

(3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSIMETRY; FEMALE; HUMAN; MALE; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUTROPHIL; PRESCRIPTION; REPEATED DRUG DOSE; TUMOR VOLUME; BONE MARROW; NEUROENDOCRINE TUMORS; PRESCHOOL CHILD; RADIATION DOSE; RADIATION RESPONSE; SCINTISCANNING; WHOLE BODY COUNTING; YOUNG ADULT;

3-IODOBENZYLGUANIDINE; ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; NEUROENDOCRINE TUMORS; RADIONUCLIDE IMAGING; RADIOTHERAPY DOSAGE; WHOLE-BODY COUNTING; YOUNG ADULT;

EID: 84934997535     PISSN: 00942405     EISSN: 24734209     Source Type: Journal    
DOI: 10.1118/1.4921807     Document Type: Article

References (41)

1. J. A. O'Neill, P. Littman, P. Blitzer, K. Soper, J. Chatten, and H. Shimada, " The role of surgery in localized neuroblastoma," J. Pediatr. Surg. 20, 708-712 (1985). 10.1016/s0022-3468(85)80029-4
2. G. Akerström and P. Hellman, " Surgery on neuroendocrine tumors," Best Pract. Res., Clin. Endocrinol. Metab. 21, 87-109 (2007). 10.1016/j.beem.2006.12.004
3. J. C. Sisson and G. A. Yanik, " Theranostics: Evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors," Semin. Nucl. Med. 42, 171-184 (2012). 10.1053/j.semnuclmed.2011.11.004
4. 131I-meta-iodobenzylguanidine (131I-mIBG) therapy," Eur. J. Nucl. Med. Mol. Imaging 35, 1039-1047 (2008). 10.1007/s00259-008-0715-3
5. K. C. Loh, P. A. Fitzgerald, K. K. Matthay, P. P. Yeo, and D. C. Price, " The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients," J. Endocrinol. Invest. 20 (11), 648-658 (1997). 10.1007/BF03348026
6. E. M. Prvulovich, R. C. Stein, J. B. Bomanji, J. A. Ledermann, I. Taylor, and P. J. Eli, " Iodine-131-MIBG therapy of a patient with carcinoid liver metastases," J. NucI. Med. 39, 1743-1745 (1998).
7. S. G. DuBois and K. K. Matthay, " Radiolabeled meaiodobenzylguanidine for the treatment of neuroblastoma," Nucl. Med. Biol. 35, 35-48 (2008). 10.1016/j.nucmedbio.2008.05.002
8. G. Gnanasegaran, N. Kapse, and J. R. Buscombe, " Recent trends in radionuclide imaging and targeted radionuclide therapy of neuroendocrine tumors," Indian J. Nucl. Med. 20, 55-66 (2005).
9. 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma," Eur. J. Nucl. Med. Mol. Imaging 37, 1279-1290 (2010). 10.1007/s00259-010-1391-7
10. M. N. Gaze and N. L. Fersht, " Current experience with mIBG therapy in combination with chemotherapy and radiosensitizers," Nucl. Med. Biol. 35, 21-26 (2008). 10.1016/j.nucmedbio.2008.05.004
11. J. Toporski, M. Garkavij, J. Tennvall, I. Ora, K. S. Gleisner, J. H. Dykes, S. Lenhoff, G. Juliusson, S. Scheding, D. Turkiewicz, and A. N. Bekassy, " High-dose iodine-131-metaiodobenzylguanadine with haploidentical stem cell transplantation and posttransplant inmunotherapy in children with relapsed/refractory neuroblastoma," Biol. Blood Marrow Transplant. 15, 1077-1085 (2009). 10.1016/j.bbmt.2009.05.007
12. C. Chiesa, R. Castellani, M. Mira, A. Lorenzoni, and G. D. Flux, " Dosimetry in 131I-MIBG therapy: Moving toward personalized medicine," Q. J. Nucl. Med. Mol. Imaging 57, 161-170 (2013).
13. 131I-mIBG therapy in metastatic phaeochromocytoma and paraganglioma," Eur. J. Nucl. Med. Mol. Imaging 35, 725-733 (2008). 10.1007/s00259-007-0652-6
14. S. D. Safford, R. E. Coleman, J. P. Gockerman, J. Moore, J. M. Feldman, G. S. Leight, D. S. Tyler, and J. Olson, " Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma," Surgery 134 (6), 956-962 (2003). 10.1016/S0039-6060(03)00426-4
15. T. I. Kang, P. Brophy, M. Hickeson, S. Heyman, A. E. Evans, M. Charron, and J. M. Maris, " Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma," J. Pediatr. Hematol./Oncol. 25 (10), 769-773 (2003). 10.1097/00043426-200310000-00005
16. K. K. Matthay, A. Quach, J. Huberty, B. L. Franc, R. A. Hawkins, H. Jackson, S. Groshen, S. Shusterman, G. Yanik, J. Veatch, P. Brophy, and J. G. Villablanca, " Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study," J. Clin. Oncol. 27 (7), 1020-1025 (2009). 10.1200/JCO.2007.15.7628
17. M. N. Gaze, Y. Chang, G. D. Flux, R. J. Mairs, F. H. Saran, and S. T. Meller, " Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma," Cancer Biother. Radiopharm. 20, 195-199 (2005). 10.1089/cbr.2005.20.195
18. B. Rose, K. K. Matthay, D. Price, J. Huberty, B. Klencke, J. A. Norton, and P. A. Fitzgerald, " High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheocromocytoma," Cancer 98 (2), 239-248 (2003). 10.1002/cncr.11518
19. K. K. Matthay, J. P. Huberty, R. S. Hattner, A. R. Ablin, B. L. Engelstad, S. Zoger, B. H. Hasegawa, and D. Price, " Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma," J. Nucl. Biol. Med. 35, 244-247 (1991).
20. M. R. Castellani, S. Seghezzi, C. Chiesa, G. L. Aliberti, M. Maccauro, E. Seregni, E. Orunesu, R. Luksch, and E. Bombardieri, " (131)I-MIBG treatment of pheochromocytoma: Low versus intermediate activity regimens of therapy," Q. J. Nucl. Med. Mol. Imaging 54 (1), 100-113 (2010).
21. S. Gonias, R. Goldsby, K. K. Matthay, R. Hawkins, D. Price, J. Huberty, L. Damon, C. Linker, A. Sznewajs, S. Shiboski, and P. Fitzgerald, " Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma," J. Clin. Oncol. 27, 4162-4168 (2009). 10.1200/JCO.2008.21.3496
22. G. D. Flux, S. J. Chittenden, F. Saran, and M. N. Gaze, " Clinical applications of dosimetry for mIBG therapy," Q. J. Nucl. Med. Mol. Imaging 55, 116-125 (2011).
23. S. G. DuBois, J. Messina, J. M. Maris, J. Huberty, D. V. Glidden, J. Veatch, M. Charron, R. Hawkins, and K. K. Matthay, " Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma," J. Clin. Oncol. 22, 2452-2460 (2004). 10.1200/JCO.2004.08.058
24. 131 I -MIBG) therapy in newly diagnosed neuroblastoma patients: A retrospective analysis," Eur. J. Nucl. Med. Mol. Imaging 40, 1711-1717 (2013). 10.1007/s00259-013-2510-z
25. S. E. Buckley, S. J. Chittenden, F. H. Saran, S. T. Meller, and G. D. Flux, " Whole-body dosimetry for individualized treatment planning of 131I-mIBG radionuclide therapy for neuroblastoma," J. Nucl. Med. 50, 1518-1524 (2009). 10.2967/jnumed.109.064469
26. 131I-mIBG," J. Nucl. Med. 42, 1713-1721 (2001).
27. C. Hindorf, G. Glatting, C. Chiesa, O. Linden, and G. Flux, " EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry," Eur. J. Nucl. Med. Mol. Imaging 37, 1238-1250 (2010). 10.1007/s00259-010-1422-4
28. M. Lassmann, C. Chiesa, G. Flux, and M. Bardies, " EANM dosimetry committee guidance document: Good practice of clinical dosimetry reporting," Eur. J. Nucl. Med. Mol. Imaging 38, 192-200 (2011). 10.1007/s00259-010-1549-3
29. International Atomic Energy Agency, " Release of patients after radionuclide therapy," in Safety Report Series No. 63 (IAEA, Vienna, 2009).
30. R. Loevinger, T. Budinger, and E. Watson, MIRD Primer for Absorbed Dose Calculations (Society of Nuclear Medicine, New York, 1988).
31. A. C. Traino, M. Ferrari, M. Cremonesi, and M. G. Stabin, " Influence of whole-body mass on the scaling of S-factors for patient-specific, blood-based red marrow dosimetry," Phys. Med. Biol. 52, 5231-5248 (2007). 10.1088/0031-9155/52/17/009
32. G. D. Flux, M. J. Guy, R. Beddows, M. Pryor, and M. A. Flower, " Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy," Phys. Med. Biol. 47, 3211-3223 (2002). 10.1088/0031-9155/47/17/311
33. M. G. Stabin, " Uncertainties in internal dose calculations for radiopharmaceuticals," J. Nucl. Med. 49, 853-860 (2008). 10.2967/jnumed.107.048132
34. K. Norrgren, S. L. Svegborn, J. Areberg, and S. Mattsson, " Accuracy of the quantification of organ activity from planar gamma camera images," Cancer Biother. Radiopharm. 18, 125-131 (2003). 10.1089/108497803321269403
35. A. Trotti, A. D. Colevas, A. Setser, V. Rusch, D. Jacques, V. Budach, C. Langer, B. Murphy, R. Cumberlin, C. N. Coleman, and P. Rubin, " CTCAE v3.0: Development of a comprehensive grading system for adverse effects of cancer treatment," Semin. Radiat. Oncol. 13, 176-181 (2003). 10.1016/S1053-4296(03)00031-6
36. J. A. Siegel, " Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: Practical aspects and limitations of red marrow dosimetry," Cancer Biother. Radiopharm. 20, 126-140 (2005). 10.1089/cbr.2005.20.126
37. K. Petersson, M. Gebre-Medhin, C. Ceberg, P. Nilsson, P. Engström, T. Knöös, and E. Kjellén, " Haematological toxicity in adult patients receiving craniospinal irradiation. Indication of a dose-bath effect," Radiother. Oncol. 111, 47-51 (2014). 10.1016/j.radonc.2014.01.020
38. M. Cristy and K. Eckerman, " Specific absorbed administrations of energy at various ages from internal photon sources," in ORNL/TM-8381 V1-V7 (Oak Ridge National Laboratory, Oak Ridge, TN, 1987).
39. M. G. Stabin, R. B. Sparks, and E. Crowe, " OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine," J. Nucl. Med. 46, 1023-1027 (2005).
40. G. Sgouros, " Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations," J. Nucl. Med. 34, 689-694 (1993).
41. 3] octreotate," Eur. J. Nucl. Med. Mol. Imaging 36, 1138-1146 (2009). 10.1007/s00259-009-1072-6